Regulations.gov document
Best Practices in Developing Proprietary Names for Human Prescription Drug Products…
Notice · FDA-2014-D-0622 · posted Dec 9, 2020
Key facts
| Document ID | FDA-2014-D-0622-0020 |
|---|---|
| Title | Best Practices in Developing Proprietary Names for Human Prescription Drug Products; Guidance for Industry; Availability |
| Document type | Notice |
| Subtype | Notice of Availability |
| Agency | FDA |
| Docket | FDA-2014-D-0622 |
| Posted | Dec 9, 2020 |
| Federal Register citation | 85 FR 79189 |
| FR document number | 2020-27058 |
| Comment period opens | Dec 9, 2020 |
| Effective date | Dec 9, 2020 |
At a glance
- 1–9 Pages
- 10–99 Public comments on this docket
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About Regulations.gov documents
Regulations.gov holds the rulemaking and other documents federal agencies post for public comment. Only agency documents are published here; public submissions are not.
Source: Regulations.gov (U.S. General Services Administration eRulemaking Program) · Source date: